Market Overview:
The global sickle cell market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of sickle cell anemia, increasing awareness about the disease, and technological advancements in diagnosis and treatment of the disease. However, high cost of treatment is expected to restrain the growth of this market during the forecast period. Based on type, the global sickle cell market is segmented into diagnosis and treatment. The diagnosis segment is further sub-segmented into blood tests, imaging tests, and other tests. The treatment segment is further sub-segmented into drugs and therapies, bone marrow transplantation (BMT), stem cell therapy (SCT), erythropoietin stimulating agents (ESA), hydroxyurea therapy (HU), pain management therapies, oxygen therapy devices & services,, transfusions & chelation therapy,. Based on application,,the global sickle cell marketis dividedinto hospitals,,clinics,,and ambulatory surgical centers(ASCs). In terms of geography,., Latin America., Europe., Asia Pacific.,and Middle East & Africa.
Product Definition:
Sickle cell is a hereditary condition where the red blood cells are abnormally shaped. This can cause problems with circulation and oxygen delivery to tissues.
Diagnosis:
Diagnosis is the process through which doctors and medical specialists determine the cause of a disease. Sickle cell anemia is one such disease, in which there is a change or mutation in the genes that codes for beta-globin (HbA), leading to its abnormal hemoglobin production. The abnormal hemoglobin causes complications during pregnancy, affecting both mother and child; it can lead to severe brain damage in infants after they are born.
Treatment:
Treatment is the process through which doctors and medical practitioners try to restore a patients’ normal function by curing the disease or condition. Sickle cell anemia is one such disease or condition in which there is a change or mutation in genes that causes abnormal hemoglobin production.
These three abnormalities make the red blood cells rigid, sticky, and curved thereby reducing their capacity to carry oxygen to tissues.
Application Insights:
The hospitals segment dominated the global sickle cell market in 2017 and is expected to witness significant growth over the forecast period. The rising prevalence of chronic diseases, such as malaria, and an increasing number of hospital admissions for these conditions are anticipated to drive the segment. In addition, a rise in healthcare spending by governments across the world is likely to boost industry growth over the forecast period.
The clinics segment is estimated to register a CAGR exceeding 11% from 2018 to 2030 owing Sickle Cell Disease Association of America (SCDA) guidelines being followed by most clinics worldwide which has resulted in increased penetration across all regions globally.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of patients suffering from sickle cell disease, increasing healthcare expenditure and favorable government initiatives are some factors attributing to its largest share. Moreover, the availability of reimbursement coverage for treatment-related expenses is anticipated to boost the utilization rate over the forecast period.
In Asia Pacific, countries such as India and China are expected to exhibit lucrative growth during the forecast period owing to rising patient awareness levels regarding available treatments along with supportive government initiatives for early diagnosis and treatment. In addition, an increase in investments by private players for developing novel therapies will also drive this regional market during the same period.
The introduction of new diagnostic procedures coupled with growing prevalence rates is anticipated to fuel demand across Latin America over the projected time frame; however, stringent regulatory guidelines may act as a restraint force until 2018 or later years due to which it may not achieve its full potential growth rate compared with other regions mentioned above (i.
Growth Factors:
- Increasing awareness about sickle cell disease and its management among people.
- Growing number of research studies on the disease and new treatment options being developed.
- Rising incidence of sickle cell anemia in developing countries due to improved diagnosis rates and population growth.
- increasing government support for initiatives to improve access to care for patients with sickle cell anemia.
Scope Of The Report
Report Attributes
Report Details
Report Title
Sickle Cell Market Research Report
By Type
Diagnosis, Treatment
By Application
Hospitals, Clinics, Ambulatory Surgical Centers
By Companies
Novartis, Bristol-Myers Squibb, Takeda, Bluebird Bio, Global Blood Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
138
Number of Tables & Figures
97
Customization Available
Yes, the report can be customized as per your need.
Global Sickle Cell Market Report Segments:
The global Sickle Cell market is segmented on the basis of:
Types
Diagnosis, Treatment
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Ambulatory Surgical Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Bristol-Myers Squibb
- Takeda
- Bluebird Bio
- Global Blood Therapeutics
Highlights of The Sickle Cell Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Diagnosis
- Treatment
- By Application:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sickle Cell Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Sickle Cell is a genetic disorder that affects the red blood cells. People with sickle cell have an abnormal hemoglobin molecule, which can cause their red blood cells to become twisted and misshapen. This can lead to problems with how well the cells carry oxygen throughout the body, including during exercise.
Some of the major players in the sickle cell market are Novartis, Bristol-Myers Squibb, Takeda, Bluebird Bio, Global Blood Therapeutics.
The sickle cell market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Sickle Cell Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Sickle Cell Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Sickle Cell Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Sickle Cell Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Sickle Cell Market Size & Forecast, 2020-2028
4.5.1 Sickle Cell Market Size and Y-o-Y Growth
4.5.2 Sickle Cell Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Diagnosis
5.2.2 Treatment
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Ambulatory Surgical Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Sickle Cell Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Sickle Cell Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Diagnosis
9.6.2 Treatment
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Ambulatory Surgical Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Diagnosis
10.6.2 Treatment
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Ambulatory Surgical Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Diagnosis
11.6.2 Treatment
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Ambulatory Surgical Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Diagnosis
12.6.2 Treatment
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Ambulatory Surgical Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Diagnosis
13.6.2 Treatment
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Ambulatory Surgical Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Sickle Cell Market: Competitive Dashboard
14.2 Global Sickle Cell Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Bristol-Myers Squibb
14.3.3 Takeda
14.3.4 Bluebird Bio
14.3.5 Global Blood Therapeutics
